SF3B1 and myelodysplastic syndrome: Through an expanded analysis of 7,017 patients on behalf of the International Consortium for MDS [47], Komrokji et al. documented that genetically defined entities (SF3B1, del5q, and biTP53) were unique, and the survival of patients with LB and RS (wild-type SF3B1) was similar to that of patients with MDS-LB.